Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec;19(12):2965-76.
doi: 10.1007/s00330-009-1504-5.

Pretreatment evaluation of distant-site status in patients with nasopharyngeal carcinoma: accuracy of whole-body MRI at 3-Tesla and FDG-PET-CT

Affiliations

Pretreatment evaluation of distant-site status in patients with nasopharyngeal carcinoma: accuracy of whole-body MRI at 3-Tesla and FDG-PET-CT

Shu-Hang Ng et al. Eur Radiol. 2009 Dec.

Abstract

We sought to prospectively evaluate the accuracy of 3.0-Tesla whole-body magnetic resonance imaging (WB-MRI) and integrated fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) (FDG-PETCT), and their combined interpretation for the assessment of distant-site status in 150 patients with untreated nasopharyngeal carcinoma (NPC). Eighteen (12%) patients were diagnosed as having distant malignancies (15 patients had distant metastases, and three distant synchronous tumours). On a patient-based analysis, WB-MRI and FDG-PET-CT showed similar sensitivity (77.8% vs 72.2%, P>0.999), specificity (98.5% vs 97.7%, P > 0.999) and diagnostic capability (0.905 vs 0.878, P = 0.669). Combined interpretation of WB-MRI and FDGPET-CT showed no significant benefit over either technique alone. In conclusion, 3.0-Tesla WB-MRI is a feasible, non-ionising technique that showed similar diagnostic capacity to FDG-PET-CT in assessing distant-site status in patients with untreated NPC and can be recommended as the first-line imaging technique for comprehensive evaluation of such patients.

PubMed Disclaimer

References

    1. Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):12-22 - PubMed
    1. J Clin Oncol. 2006 Feb 1;24(4):599-604 - PubMed
    1. Semin Musculoskelet Radiol. 2001;5(1):5-20 - PubMed
    1. Cancer. 1993 Jan 15;71(2):452-6 - PubMed
    1. Radiology. 2008 Mar;246(3):675-96 - PubMed

Publication types

Substances